Ending virus-driven cancer

Best-in-class
virus-targeted immunotherapies, in oncology and beyond

Introduction

Pioneering immunotherapy to treat virus-driven disease

Globally, each year, nearly 1.4 million new cancer cases are ascribed to viral infections, accounting for 8% of all cancers. Infections are the second leading preventable cause of cancer worldwide, after tobacco and ahead of alcohol.

With our team of specialists, we have developed Launch-iT, a novel platform to create virus-targeted immunotherapies that address some of today’s most urgent medical needs in oncology and beyond.

About

Virus-driven Cancer

A new therapeutic space

We develop immunotherapies to eliminate the virus before it causes cancer. Our approach opens a new therapeutic space alongside prevention and treatment, bringing hope to millions of people who know they are at risk of cancer but currently have no therapeutic option.

Healthy
Screening NEGATIVE
Prevent cancer
Reduce risks:
e.g. Preventive vaccines
Infection / Pre-cancer
Screening POSITIVE
Intercept cancer
Virus: Targeted
Immunotherapy

New Astrivax treatment
Cancer
Screening POSITIVE
Treat cancer
Immunotherapy, e.g.
checkpoint inhibitors

See how we address this?

Technology

Human papilloMa virus (HPV)

Ending HPV-driven cancer

HPV is a highly prevalent virus, with most individuals infected at some point in their lives, often without symptoms. While the immune system clears the infection in most cases, persistent infection with high-risk HPV types can lead to cancer. HPV is responsible for nearly all cases of cervical cancer and contributes to a growing number of head and neck and other anogenital cancers worldwide.

See how we address this?

Pipeline